Total Valuation
Reyon Pharmaceutical Co., Ltd. has a market cap or net worth of ₩185.06B. The enterprise value is ₩396.16K.
Market Cap₩185.06B
Enterprise Value₩396.16K
Share Statistics
Reyon Pharmaceutical Co., Ltd. has 18,586,811 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,586,811
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Reyon Pharmaceutical Co., Ltd.’s return on equity (ROE) is -0.14 and return on invested capital (ROIC) is -7.20%.
Return on Equity (ROE)-0.14
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-7.20%
Return on Capital Employed (ROCE)-0.10
Revenue Per Employee319.32M
Profits Per Employee-65.26M
Employee Count457
Asset Turnover0.31
Inventory Turnover2.96
Valuation Ratios
The current PE Ratio of Reyon Pharmaceutical Co., Ltd. is ―. Reyon Pharmaceutical Co., Ltd.’s PEG ratio is 0.00830.
PE Ratio―
PS Ratio1.37
PB Ratio0.91
Price to Fair Value0.91
Price to FCF-29.97
Price to Operating Cash Flow31.25
PEG Ratio0.00830
Income Statement
In the last 12 months, Reyon Pharmaceutical Co., Ltd. had revenue of 145.93B and earned -29.83B in profits. Earnings per share was -1.60K.
Revenue145.93B
Gross Profit33.76B
Operating Income-31.57B
Pretax Income-24.67B
Net Income-29.83B
EBITDA228.10M
Earnings Per Share (EPS)-1.60K
Cash Flow
In the last 12 months, operating cash flow was 5.95B and capital expenditures -5.04B, giving a free cash flow of 906.03M billion.
Operating Cash Flow5.95B
Free Cash Flow906.03M
Free Cash Flow per Share48.75
Dividends & Yields
Reyon Pharmaceutical Co., Ltd. pays an annual dividend of ₩177, resulting in a dividend yield of 1.41%
Dividend Per Share₩177
Dividend Yield1.41%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.17
52-Week Price Change-11.60%
50-Day Moving Average10.07K
200-Day Moving Average10.60K
Relative Strength Index (RSI)56.40
Average Volume (3m)33.54K
Important Dates
Reyon Pharmaceutical Co., Ltd. upcoming earnings date is Nov 12, 2026, TBA (Confirmed).
Last Earnings DateAug 14, 2026
Next Earnings DateNov 12, 2026
Ex-Dividend Date―
Financial Position
Reyon Pharmaceutical Co., Ltd. as a current ratio of 0.56, with Debt / Equity ratio of 111.28%
Current Ratio0.56
Quick Ratio0.29
Debt to Market Cap1.07
Net Debt to EBITDA918.23
Interest Coverage Ratio-2.39
Taxes
In the past 12 months, Reyon Pharmaceutical Co., Ltd. has paid 5.02B in taxes.
Income Tax5.02B
Effective Tax Rate-0.20
Enterprise Valuation
Reyon Pharmaceutical Co., Ltd. EV to EBITDA ratio is 1.80K, with an EV/FCF ratio of -61.29.
EV to Sales2.81
EV to EBITDA1.80K
EV to Free Cash Flow-61.29
EV to Operating Cash Flow333.45
Balance Sheet
Reyon Pharmaceutical Co., Ltd. has ₩7.04B in cash and marketable securities with ₩216.85B in debt, giving a net cash position of -₩209.82B billion.
Cash & Marketable Securities₩7.04B
Total Debt₩216.85B
Net Cash-₩209.82B
Net Cash Per Share-₩11.29K
Tangible Book Value Per Share₩11.61K
Margins
Gross margin is 21.48%, with operating margin of -21.63%, and net profit margin of -20.44%.
Gross Margin21.48%
Operating Margin-21.63%
Pretax Margin-16.90%
Net Profit Margin-20.44%
EBITDA Margin0.16%
EBIT Margin-21.63%
Analyst Forecast
The average price target for Reyon Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-4.45%
EPS Growth Forecast-250.71%